PRODUCT CODE: em1707-60

PD1 Monoclonal Antibody (EM1707-60)

  • IVD–IHC

Applications

  • WB

  • ICC

  • IHC-P

  • FC

REACTIVITY

  • Human

Western blot analysis of PD1 on PD1 transfected 293FT cell lysate using anti-PD1 antibody at 1/1,000 dilution.
  • Western blot analysis of PD1 on PD1 transfected 293FT cell lysate using anti-PD1 antibody at 1/1,000 dilution.
  • Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-PD1 antibody. Counter stained with hematoxylin.
  • Flow cytometric analysis of Jurkat cells with PD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Western blot analysis of PD1 on PD1 transfected 293FT cell lysate using anti-PD1 antibody at 1/1,000 dilution.

Applications

  • WB

  • ICC

  • IHC-P

  • FC

REACTIVITY

  • Human

SPECIFICATIONS

Product Type

Mouse monoclonal primary

Product Name

PD1 Monoclonal Antibody (EM1707-60)

Immunogen

Recombinant protein

Host

Mouse

Positive Control

Human tonsil tissue, Mouse spleen tissue, Jurkat, recombinant PD1 protein.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

1F2

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*PBS (pH7.4), 0.2% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

2 ug/ul

PURIFICATION

Protein A purified.

MOLECULAR WEIGHT

32 kDa

Isotype

IgG1

APPLICATION DILUTION

  • WB

  • 1:500-1:2,000

  • ICC

  • 1:50-1:200

  • IHC-P

  • 1:100-1:500

  • FC

  • 1:50-1:100

TARGET

UNIPROT #

PROTEIN NAME

Programmed cell death protein 1

GENE NAME

PDCD1

SYNONYMS

Protein PD-1, hPD-1, PDCD1, PD1

DEVELOPMENTAL STAGE

Induced at programmed cell death.

POST-TRANSLATIONAL MODIFICATION

Ubiquitinated at Lys-233 by the SCF(FBXO38) complex, leading to its proteasomal degradation. Ubiquitinated via 'Lys-48'-linked polyubiquitin chains.; Tyrosine phosphorylated at Tyr-223 (within ITIM motif) and Tyr-248 (ITSM motif) upon ligand binding. Phosphorylation at Tyr-248 promotes the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta.; N-glycosylation at Asn-58 consists of two N-acetylglucosamine units and one fucose. N-glycosylation does not affect binding to nivolumab drug.

SUBCELLULAR LOCATION

Cell membrane; Single-pass type I membrane protein.

FUNCTION

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity).; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.